CEO, Myricx Bio
| Role | Organisation | Sources |
|---|---|---|
| CEO | Myricx Bio | Forbes Australia, Brandon Capital portfolio |
Stories naming Mohit Rawat. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Novartis is acquiring London biotech Myricx Bio for US$1.1 billion upfront plus milestone payments, handing Melbourne venture firm Brandon Capital a record return on the startup it seeded in 2019.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com